Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 (TAB1) is a crucial adaptor protein and pseudophosphatase that plays a pivotal role in intracellular signaling cascades. It constitutively associates with the N-terminal catalytic domain of MAP3K7 (also known as TAK1), facilitating its autophosphorylation and subsequent activation in response to pro-inflammatory cytokines, Toll-like receptor (TLR) ligands, and TGF-beta. Additionally, TAB1 directly interacts with and induces the non-canonical autoactivation of MAPK14 (p38alpha), representing an alternative pathway to classical MAPKK activation. Through these interactions, TAB1 serves as a key mediator of downstream NF-kappa-B and MAPK signaling pathways, which regulate essential cellular processes such as inflammation, immune responses, cell survival, and apoptosis.\n\nDysregulation of TAB1-mediated signaling is heavily implicated in chronic inflammatory disorders, autoimmune diseases, and various cancers, where it promotes tumor cell survival, invasion, and metastasis. Consequently, the TAK1-TAB1 complex and the p38alpha-TAB1 interaction have emerged as attractive therapeutic targets. While direct small-molecule inhibitors of TAB1 are still in early development, several pharmacological agents, such as the selective TAK1 inhibitor takinib and the type II inhibitor NG25, target the active TAK1-TAB1 complex to suppress downstream inflammatory signaling. Furthermore, targeting the specific protein-protein interaction interface between p38alpha and TAB1 with small molecules or peptide inhibitors represents a promising strategy to selectively block stress-induced p38alpha activation while avoiding the systemic toxicities associated with global p38alpha kinase inhibition.
Inhibition of the TAK1-TAB1 complex, disruption of the p38-TAB1 protein-protein interaction, or allosteric modulation of downstream kinase activation.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 (TAB1) (TAB1).